SM
AXN

Sabby Management’s Aoxing Pharmaceutical Company Inc. AXN Stock Holding History

Sabby Management’s Portfolio AXN Stock Details AXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,134,054
Closed -$3.16M – 409
2015
Q3 		$3.16M Buy
+2,134,054
New +$3.36M 0.13% 119

Other funds holding AXN

VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RCM
Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
MA
MUFG Americas New York $4.04B AUM 12.45% 1-Year Est. Return

Sabby Management's AXN Position: Q4 2015 in Review

Sabby Management sold out of Aoxing Pharmaceutical Company Inc. (AXN) in Q4 2015, closing a stake of 2,134,054 shares — an estimated $3.16M sold.

Sabby Management first reported a position in AXN in Q3 2015 and held it in 1 quarter. The position peaked at $3.16M in Q3 2015. 14 funds tracked by Wall St. Rank hold AXN as of Q4 2015.

  • Sabby Management reported no remaining Aoxing Pharmaceutical Company Inc. position as of Q4 2015 after selling out during the quarter.
  • Sabby Management sold 2,134,054 Aoxing Pharmaceutical Company Inc. shares in Q4 2015, an estimated $3.16M.
  • Sabby Management first reported a position in Aoxing Pharmaceutical Company Inc. in Q3 2015 and held it in 1 quarter.
  • Sabby Management's Aoxing Pharmaceutical Company Inc. position peaked at $3.16M in Q3 2015.
  • 14 funds tracked by Wall St. Rank held Aoxing Pharmaceutical Company Inc. as of Q4 2015.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.